{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:28:44Z","timestamp":1784834924369,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012453","name":"Providence Health Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bioethical Inquiry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11673-024-10387-3","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T06:16:42Z","timestamp":1730096202000},"page":"615-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicians\u2019 Perspectives and an Ethical Analysis of Safer Supply Opioid Prescribing"],"prefix":"10.1007","volume":"22","author":[{"given":"Kathleen","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Genuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-8035","authenticated-orcid":false,"given":"Sarah","family":"Ickowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"3","key":"10387_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.15288\/jsad.2022.83.309","volume":"83","author":"G Bardwell","year":"2022","unstructured":"Bardwell, G. 2022. More than a pipe dream? The need to adapt safer opioid supply programs for people who smoke drugs. Journal of Studies on Alcohol and Drugs 83(3): 309\u2013311.","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10387_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13011-023-00525-2","volume":"18","author":"G Bardwell","year":"2023","unstructured":"Bardwell, G., J.M. Bowles, M. Mansoor, D. Werb, and T. Kerr. 2023. Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: A qualitative study. Substance Abuse Treatment, Prevention and Policy 18: 14.","journal-title":"Substance Abuse Treatment, Prevention and Policy"},{"key":"10387_CR3","doi-asserted-by":"crossref","unstructured":"Bardwell, G., A. Ivsins, M.E. Soc\u00edas, and T. Kerr. 2021a. Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada. Journal of Substance Abuse Treatment 130: 108418.","DOI":"10.1016\/j.jsat.2021.108418"},{"key":"10387_CR4","doi-asserted-by":"crossref","unstructured":"Bardwell, G., W. Small, J. Lavalley, R. McNeil, and T. Kerr. 2021b. \"People need them or else they\u2019re going to take fentanyl and die\": A qualitative study examining the \"problem\" of prescription opioid diversion during an overdose epidemic. Social Science & Medicine 279: 113986.","DOI":"10.1016\/j.socscimed.2021.113986"},{"key":"10387_CR5","volume-title":"Principles of biomedical ethics","author":"T Beauchamp","year":"2019","unstructured":"Beauchamp, T., and J. Childress. 2019. Principles of biomedical ethics. 8th ed. Oxford: Oxford University Press.","edition":"8"},{"key":"10387_CR6","unstructured":"British Columbia Centre for Disease Control. 2021a. Post-mortem detection of hydromorphone among persons identified as having an illicit drug toxicity death since the introduction of risk mitigation guidance prescribing. September 15. http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/Overdose\/2021.09.15_Knowledge%20Update_Hydromorphone%20and%20drug%20toxicity%20deaths.pdf. Accessed October 11, 2023."},{"key":"10387_CR7","unstructured":"____. 2021b. Post-mortem detection of hydromorphone among persons identified as having an illicit drug toxicity death since the introduction of risk mitigation guidance prescribing: Toxicology supplement. http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/Overdose\/20211209_BCCDC%20Knowledge%20Update_RMG%20Evaluation%20Hydromorphone%20Tox%20Supplement.pdf. Accessed June 19, 2024."},{"key":"10387_CR8","unstructured":"British Columbia Centre on Substance Use. 2019. Heroin compassion clubs. February. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2019\/02\/Report-Heroin-Compassion-Clubs.pdf. Accessed October 11, 2023."},{"key":"10387_CR9","unstructured":"____. 2022. Fentanyl patch: Prescribed safer supply protocols. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/10\/Prescribed-Safer-Supply-Protocols-Fentanyl-Patch.pdf. Accessed October 11, 2023."},{"key":"10387_CR10","unstructured":"____. 2023. Prescribed safer supply protocols: Sufentanil. September. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/09\/PSS-Protocols-Sufentanil.pdf. Accessed October 11, 2023."},{"key":"10387_CR11","unstructured":"British Columbia Centre on Substance Use, BC Ministry of Health, and Ministry of Mental Health and Addictions. 2022. Risk mitigation in the context of dual health emergencies\u2014interim clinical guidance: Update. January. https:\/\/www.bccsu.ca\/COVID-19. Accessed October 11, 2023."},{"key":"10387_CR12","unstructured":"British Columbia Coroners Service. 2024. Youth unregulated drug toxicity deaths in British Columbia. May 29. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/youth_unregulated_drug_toxicity_deaths_in_bc_2019-2023.pdf. Accessed October 10, 2023."},{"key":"10387_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109440","volume":"235","author":"TD Brothers","year":"2022","unstructured":"Brothers, T.D., M. Leaman, M. Bonn, et al. 2022. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug and Alcohol Dependence 235: 109440.","journal-title":"Drug and Alcohol Dependence"},{"key":"10387_CR14","doi-asserted-by":"publisher","unstructured":"Canadian Association of People Who Use Drugs. 2019. Safe supply concept document. https:\/\/doi.org\/10.5281\/ZENODO.5637606.","DOI":"10.5281\/ZENODO.5637606"},{"issue":"4","key":"10387_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.15288\/jsad.2022.83.621","volume":"83","author":"KE Dunn","year":"2022","unstructured":"Dunn, K.E. 2022. Advocating for a thoughtful expansion of safer supply to realize bold impact on opioid overdose. Journal of Studies on Alcohol and Drugs 83(4): 621\u2013622.","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"6","key":"10387_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jme-2021-108087","volume":"49","author":"K Duthie","year":"2023","unstructured":"Duthie, K., E. Mathison, H. Eyford, and S.M. Ghosh. 2023. Prescribing safe supply: Ethical considerations for clinicians. Journal of Medical Ethics 49(6): 377\u2013382.","journal-title":"Journal of Medical Ethics"},{"issue":"1","key":"10387_CR17","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.9778\/cmajo.20200021","volume":"9","author":"E Eydt","year":"2021","unstructured":"Eydt, E., S. Glegg, C. Sutherland, et al. 2021. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. CMAJ Open 9(1): E115\u2013124.","journal-title":"CMAJ Open"},{"key":"10387_CR18","unstructured":"Federal, Provincial, and Territorial Special Advisory Committee on the Epidemic of Opioid Overdoses. 2023. Opioid- and stimulant-related harms in Canada. Ottawa: Public Health Agency of Canada, September. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants. Accessed October 11, 2023."},{"key":"10387_CR19","doi-asserted-by":"crossref","unstructured":"Ferri, M., M. Davoli, and C.A. Perucci. 2011. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews 2011(12): CD003410.","DOI":"10.1002\/14651858.CD003410.pub3"},{"issue":"1","key":"10387_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-022-00494-y","volume":"17","author":"A Foreman-Mackey","year":"2022","unstructured":"Foreman-Mackey, A., B. Pauly, A. Ivsins, K. Urbanoski, M. Mansoor, and G. Bardwell. 2022. Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada. Substance Abuse Treatment, Prevention and Policy 17(1): 1\u201311.","journal-title":"Substance Abuse Treatment, Prevention and Policy"},{"key":"10387_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103805","volume":"108","author":"ND Gehring","year":"2022","unstructured":"Gehring, N.D., K.A. Speed, T.C. Wild, B. Pauly, G. Salvalaggio, and E. Hyshka. 2022. Policy actor views on structural vulnerability in harm reduction and policymaking for illegal drugs: A qualitative study. The International Journal of Drug Policy 108: 103805.","journal-title":"The International Journal of Drug Policy"},{"issue":"3","key":"10387_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/jmp\/jhab004","volume":"46","author":"QIT Genuis","year":"2021","unstructured":"Genuis, Q.I.T. 2021. A genealogy of autonomy: Freedom, paternalism, and the future of the doctor\u2013patient relationship. The Journal of Medicine and Philosophy 46(3): 330\u2013349.","journal-title":"The Journal of Medicine and Philosophy"},{"key":"10387_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104023","volume":"115","author":"K Giang","year":"2023","unstructured":"Giang, K., R. Charlesworth, M. Thulien, et al. 2023. Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies. The International Journal of Drug Policy 115: 104023.","journal-title":"The International Journal of Drug Policy"},{"key":"10387_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742","volume":"106","author":"S Glegg","year":"2022","unstructured":"Glegg, S., K. McCrae, G. Kolla, et al. 2022. \"COVID just kind of opened a can of whoop-ass\": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. The International Journal of Drug Policy 106: 103742.","journal-title":"The International Journal of Drug Policy"},{"issue":"36","key":"10387_CR25","doi-asserted-by":"publisher","first-page":"E1233","DOI":"10.1503\/cmaj.220892","volume":"194","author":"T Gomes","year":"2022","unstructured":"Gomes, T., G. Kolla, D. McCormack, A. Sereda, S. Kitchen, and T. Antoniou. 2022. Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario. CMAJ 194(36): E1233\u2013E1242.","journal-title":"CMAJ"},{"key":"10387_CR26","unstructured":"Government of Canada: Health Canada. 2022. Early findings from safer supply pilot projects. March 17. https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply\/early-findings-safer-supply-pilot-projects.html. Accessed October 11, 2023."},{"key":"10387_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-023-00776-z","volume":"20","author":"M Haines","year":"2023","unstructured":"Haines, M., and P. O\u2019Byrne. 2023. Safer opioid supply: Qualitative program evaluation. Harm Reduction Journal 20: 53.","journal-title":"Harm Reduction Journal"},{"key":"10387_CR28","doi-asserted-by":"crossref","unstructured":"Ivsins, A., J. Boyd, L. Beletsky, and R. McNeil. 2020. Tackling the overdose crisis: The role of safe supply. The International Journal of Drug Policy 80: 102769.","DOI":"10.1016\/j.drugpo.2020.102769"},{"key":"10387_CR29","doi-asserted-by":"crossref","unstructured":"Ivsins, A., J. Boyd, S. Mayer, et al. 2020. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: A qualitative study. Drug and Alcohol Dependence 216: 108202.","DOI":"10.1016\/j.drugalcdep.2020.108202"},{"issue":"1","key":"10387_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11524-020-00489-9","volume":"98","author":"A Ivsins","year":"2021","unstructured":"____. 2021. \"It\u2019s helped me a lot, just like to stay alive\": A qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. Journal of Urban Health 98(1): 59\u201369.","journal-title":"Canada. Journal of Urban Health"},{"issue":"5","key":"10387_CR31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11524-022-00679-7","volume":"99","author":"A Ivsins","year":"2022","unstructured":"Ivsins, A., L. MacKinnon, J.M. Bowles, A. Slaunwhite, and G. Bardwell. 2022. Overdose prevention and housing: A qualitative study examining drug use, overdose risk, and access to safer supply in permanent supportive housing in Vancouver, Canada. Journal of Urban Health 99(5): 855\u2013864.","journal-title":"Canada. Journal of Urban Health"},{"issue":"19","key":"10387_CR32","doi-asserted-by":"publisher","first-page":"E674","DOI":"10.1503\/cmaj.211515","volume":"194","author":"S Klaire","year":"2022","unstructured":"Klaire, S., C. Sutherland, T. Kerr, and M.C. Kennedy. 2022. A low-barrier, flexible safe supply program to prevent deaths from overdose. Canadian Medical Association Journal 194(19): E674\u2013E676.","journal-title":"Canadian Medical Association Journal"},{"issue":"1","key":"10387_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-022-00614-8","volume":"19","author":"B Lew","year":"2022","unstructured":"Lew, B., C. Bodkin, R. Lennox, T. O\u2019Shea, G. Wiwcharuk, and S. Turner. 2022. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: A case study. Harm Reduction Journal 19(1): 29.","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10387_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-022-00657-x","volume":"19","author":"K McCrae","year":"2022","unstructured":"McCrae, K., S. Glegg, M.\u00c9. Goyer, et al. 2022. The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19. Harm Reduction Journal 19(1): 1\u201377.","journal-title":"Harm Reduction Journal"},{"issue":"S2","key":"10387_CR35","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2105\/AJPH.2021.306692","volume":"112","author":"R McNeil","year":"2022","unstructured":"McNeil, R., T. Fleming, S. Mayer, et al. 2022. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021. American Journal of Public Health 112(S2): S151\u2013S158.","journal-title":"American Journal of Public Health"},{"key":"10387_CR36","unstructured":"Ministry of Mental Health and Addictions and Ministry of Health. 2021. Access to prescribed safer supply in British Columbia: Policy direction, July. https:\/\/www2.gov.bc.ca\/assets\/gov\/overdose-awareness\/prescribed_safer_supply_in_bc.pdf. Accessed May 5, 2024."},{"issue":"6","key":"10387_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048353","volume":"11","author":"B Nosyk","year":"2021","unstructured":"Nosyk, B., A. Slaunwhite, K. Urbanoski, et al. 2021. Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: A mixed-method study protocol. BMJ Open 11(6): e048353.","journal-title":"BMJ Open"},{"key":"10387_CR38","doi-asserted-by":"crossref","unstructured":"Olding, M., A. Ivsins, S. Mayer, et al. 2020. A low-barrier and comprehensive community-based harm-reduction site in Vancouver, Canada. American Journal of Public Health (1971) 110(6): 833\u2013835.","DOI":"10.2105\/AJPH.2020.305612"},{"issue":"8","key":"10387_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes, E., S. Brissette, D.C. Marsh, et al. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. The New England Journal of Medicine 361(8): 777\u2013786.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10387_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12913-023-09558-6","volume":"23","author":"E Oviedo-Joekes","year":"2023","unstructured":"Oviedo-Joekes, E., S. Dobischok, J. Carvajal, et al. 2023. Clients\u2019 experiences on North America\u2019s first take-home injectable opioid agonist treatment (iOAT) program: A qualitative study. BMC Health Services Research 23(1): 553.","journal-title":"BMC Health Services Research"},{"issue":"5","key":"10387_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes, E., D. Guh, S. Brissette, et al. 2016. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial. JAMA Psychiatry 73(5): 447\u2013455.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10387_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13011-021-00358-x","volume":"16","author":"E Oviedo-Joekes","year":"2021","unstructured":"Oviedo-Joekes, E., S. MacDonald, C. Boissonneault, and K. Harper. 2021. Take home injectable opioids for opioid use disorder during and after the COVID-19 pandemic is in urgent need: A case study. Substance Abuse Treatment, Prevention, and Policy 16(1): 22.","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"4","key":"10387_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hast.1169","volume":"50","author":"TN Rieder","year":"2020","unstructured":"Rieder, T.N. 2020. Solving the opioid crisis isn\u2019t just a public health challenge\u2014it\u2019s a bioethics challenge. The Hastings Center Report 50(4): 24\u201332.","journal-title":"The Hastings Center Report"},{"key":"10387_CR44","doi-asserted-by":"crossref","unstructured":"Schmidt, R.A., N. Kaminski, D.T. Kryszajtys, et al. 2023. \"I don\u2019t chase drugs as much anymore, and I\u2019m not dead\": Client reported outcomes associated with safer opioid supply programs in Ontario, Canada. Drug and Alcohol Review, September, dar.13745.","DOI":"10.1111\/dar.13745"},{"key":"10387_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076336","volume":"384","author":"A Slaunwhite","year":"2024","unstructured":"Slaunwhite, A., J.E. Min, H. Palis, et al. 2024. Effect of risk mitigation guidance for opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: Retrospective cohort study. BMJ 384: e076336.","journal-title":"BMJ"},{"issue":"1","key":"10387_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang, J., T. Groshkova, A. Uchtenhagen, et al. 2015. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. British Journal of Psychiatry 207(1): 5\u201314.","journal-title":"British Journal of Psychiatry"},{"key":"10387_CR47","unstructured":"Time. 2021. The \"safe supply\" movement aims to curb drug deaths linked to the opioid crisis. October 25. https:\/\/time.com\/6108812\/drug-deaths-safe-supply-opioids. Accessed October 11, 2023."},{"issue":"34","key":"10387_CR48","doi-asserted-by":"publisher","first-page":"E986","DOI":"10.1503\/cmaj.201618","volume":"192","author":"M Tyndall","year":"2020","unstructured":"Tyndall, M. 2020. A safer drug supply: A pragmatic and ethical response to the overdose crisis. Canadian Medical Association Journal 192(34): E986\u2013E987.","journal-title":"Canadian Medical Association Journal"},{"issue":"1","key":"10387_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.11157\/fohpe.v23i1.544","volume":"23","author":"DF Vears","year":"2022","unstructured":"Vears, D.F., and L. Gillam. 2022. Inductive content analysis: A guide for beginning qualitative researchers. Focus on Health Professional Education: A Multi-Professional Journal 23(1): 111\u2013127.","journal-title":"Focus on Health Professional Education: A Multi-Professional Journal"},{"issue":"3","key":"10387_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/ADM.0000000000000887","volume":"16","author":"J Weng","year":"2022","unstructured":"Weng, J., N. Fairbairn, C. Sutherland, C. Johnson, and S. Nolan. 2022. Supervised tablet injectable opioid agonist therapy (TiOAT): A strategy to address safer supply for individuals with an opioid use disorder? Journal of Addiction Medicine 16(3): 258\u2013260.","journal-title":"Journal of Addiction Medicine"},{"key":"10387_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103601","volume":"102","author":"S Young","year":"2022","unstructured":"Young, S., G. Kolla, D. McCormack, et al. 2022. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. The International Journal of Drug Policy 102: 103601.","journal-title":"The International Journal of Drug Policy"}],"container-title":["Journal of Bioethical Inquiry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11673-024-10387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11673-024-10387-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11673-024-10387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:46:21Z","timestamp":1761817581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11673-024-10387-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10387"],"URL":"https:\/\/doi.org\/10.1007\/s11673-024-10387-3","relation":{},"ISSN":["1176-7529","1872-4353"],"issn-type":[{"value":"1176-7529","type":"print"},{"value":"1872-4353","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants were provided with written information about the study\u2019s background, purpose, participation structure, participant protections, planned dissemination and potential harms and benefits of participating. Verbal and written consent was provided by participants to take part in the interviews. If the interview was conducted in-person, dinner was provided. No financial or other compensation was provided. This study was approved by the Providence Health Care\u2019s Research Ethics Board (REB# H22-02787).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Considerations"}},{"value":"We have no financial or non-financial interests to disclose that are relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}